2016 American Transplant Congress
Urine-Derived Cell Lines as a Novel Tool for Monitoring Allo-Reactivity in Kidney Transplant Patients.
Reactivity of the immune system against donor antigens determines transplant-rejection after transplantation, and analyzing the alloimmune response has been shown to predict acute rejection in…2016 American Transplant Congress
Evaluating Posttransplant BKV-Specific T Cell Responses in Patients with Alemtuzumab Induction and Belatacept-Based Regimen.
Department of Surgery, Duke University, Durham, NC.
Belatacept-based maintenance regimens prevent acute allograft rejection following alemtuzumab induction, and patients so treated maintain intact anti-CMV and -EBV T cell immune responses without viral…2016 American Transplant Congress
2B4 Over-Expression Impairs Donor-Reactive CD8+ T Cell Proliferation and Accumulation Following Transplantation.
Emory Transplant Center, Emory University School of Medicine, Atlanta, GA.
T cell function is tightly regulated by a fine balance of coinhibitory signals, including those transduced by 2B4 (SLAMf4, CD244), an immunoglobulin-superfamily member constitutively expressed…2015 American Transplant Congress
Leukocyte Associated Immunoglobulin-Like Receptor 1 inhibits Th1 But Enhances Th17 Responses
Background: Leukocyte Associated Immunoglobulin-like Receptor 1 (LAIR1), is a transmembrane receptor expressed by immune cells. It recognizes collagen repeats via its extracellular domain and has…2015 American Transplant Congress
B Cell Depletion With an Anti-CD20 Antibody Enhances Alloreactive Memory T Cell Response After Transplantation
Pre-transplant B cell depletion in NHP with Rituximab (IgG1 anti-CD20 mAb) combined with cyclosporin A has been shown to promote the survival of islets allografts.…2015 American Transplant Congress
Induction of a Costimulation-Susceptible Repertoire: A Case for Depletional Prior to Belatacept
1Surgery, Duke University, Durham, NC; 2Transplant Center, Emory University, Atlanta, GA.
Belatacept offers highly specific costimulation blockade to prevent recipient alloimmune responses with reduced toxicity. However, when applied with nondepletional induction therapy belatacept-based regimens have higher…2015 American Transplant Congress
Vaccine-Induced 'Incognito' CD8+ T Cell Memory Can Disrupt Transplantation Tolerance
Transplant recipients harbor immunity to vaccines and pathogens (e.g. CMV, EBV). Pre-existing immunity can have significant antigen-specific ramifications, usually attributed to heterologous immunity, as pathogen-reactive…2015 American Transplant Congress
MDSC Derived from iPS Cells Regulate the CD8 T Cell Response In Vivo
Myeloid derived suppressor cells (MDSC) may represent a therapeutic tool for inducing tolerance in transplantation and autoimmune disorders. MDSC propagated from bone marrow (BM) can…2015 American Transplant Congress
Anti-Donor T-Cell Immunity Is a Continuum Immune Process Favouring Subclinical Rejection After Kidney Transplantation
Subclinical T-cell mediated rejection (sc-TCR) accounts for a major cause of kidney allograft loss and is unexpectedly found in a rather important number of protocol…2015 American Transplant Congress
Relative In Vitro Immunoregulatory Effects of Everolimus, Sirolimus, Tacrolimus, Mycophenolic Acid and Drug Combinations
Everolimus (EVL) is a modified form of the mTOR-inhibitor Sirolimus (SRL) and is used clinically in combination with Mycophenolate (MMF) and/or Tacrolimus (TAC). The purpose…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- Next Page »